Lv0
0 积分 2024-03-26 加入
Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)
20天前
已完结
Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous HCC
20天前
已完结
Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab
25天前
已完结
Editorial: Predictive Factors and Survival Outcome of Conversion Therapy for Unresectable Hepatocellular Carcinoma Patients Receiving Atezolizumab and Bevacizumab: Comparative Analysis of Conversion, Partial Response and Complete Response Patients
25天前
已完结
HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion
25天前
已完结
Prognosis predictors of hepatocellular carcinoma after hepatectomy following conversion therapy
26天前
已完结
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy
26天前
已完结
Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages
26天前
已完结
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan
26天前
已完结
Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients
26天前
已完结
皖公网安备34019202002308
